Introduction: Some severe hemophiliacs (FVIII/FIX<1%) exhibit a mild bleeding tendency, but the basis for this clinical heterogeneity is poorly understood. This study investigated the relationship between the values of endogenous thrombin potential (ETP) and clinical phenotype in severe hemophiliacs. The impact of FVIII/FIX gene mutations and thrombophilic polymorphisms was also evaluated. Methods: severe hemophiliacs older than 18 years without inhibitor history and treated on demand were eligible. Mild bleeders (MB) and severe bleeders (SB) were defined as follows: spontaneous bleeding episodes per year ≤2 (MB) or 25 (SB) and concentrate consumption <500 (MB) or >2000 (SB) IU/Kg/year. Patients who did not fit these criteria were considered as intermediate bleeders (IB). FVIII was measured by chromogenic assay and ETP was measured in platelet-rich plasma after addition of tissue factor. Results: 22MB, 22SB and 28IB were enrolled. MB had lower clinical and radiological scores when compared with both IB and SB (p<0.005). MB showed an older age at first bleed compared to SB (p < 0.005) and p for trend among the 3 groups was also significant (p < 0.05). The prevalence of severe FVIII/FIX gene defects (null mutations) was lower and ETP values were higher in MB compared with both IB and SB (p<0.05; table 1). Conclusions: our results indicate an extremely low prevalence of null mutations in severe hemophiliacs with mild bleeding diathesis. The measurement of thrombin generation in platelet-rich plasma may allow to identify this subgroup of patients, not otherwise distinguishable by conventional functional assays.

SB (#22)IB (#28)MB (#22)p
Age (yr) 38 (21–76) 38 (23–62) 32 (22–73) NS 
Age 1st bleed (yr) 1 (0–4) 2 (0–6) 3 (1–10) < 0.005 
Bleeding episodes/yr 36 (25–60) 10 (3–20) 0 (0–2) < 0.0005 
Factor use (IU/Kg/yr) 2207 (2040–8696) 1068 (207–2400) 60 (25–487) < 0.0005 
Clinical score 18 (10–35) 10 (0–34) 3 (0–17) < 0.005 
Pettersson score 44 (14–62) 28 (0–48) 17 (3–40) < 0.0005 
Null mutations (%) 59 70 < 0.005 
PTG20210A (%) NS 
FV Leiden (%) NS 
Median ETP (nM) 414 478 850 < 0.05 
SB (#22)IB (#28)MB (#22)p
Age (yr) 38 (21–76) 38 (23–62) 32 (22–73) NS 
Age 1st bleed (yr) 1 (0–4) 2 (0–6) 3 (1–10) < 0.005 
Bleeding episodes/yr 36 (25–60) 10 (3–20) 0 (0–2) < 0.0005 
Factor use (IU/Kg/yr) 2207 (2040–8696) 1068 (207–2400) 60 (25–487) < 0.0005 
Clinical score 18 (10–35) 10 (0–34) 3 (0–17) < 0.005 
Pettersson score 44 (14–62) 28 (0–48) 17 (3–40) < 0.0005 
Null mutations (%) 59 70 < 0.005 
PTG20210A (%) NS 
FV Leiden (%) NS 
Median ETP (nM) 414 478 850 < 0.05 

Disclosures: No relevant conflicts of interest to declare.

Author notes

Corresponding author

Sign in via your Institution